Drugs / CYAD-101
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04991948 | Nov 2021 → Aug 2023 overdue | colorectal cancer | Celyad Oncology SA | Recruiting | No outcome recorded |
| Phase 1 | NCT03692429 | Nov 2018 → Nov 2021 overdue | colorectal cancer | Celyad Oncology SA | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYAD-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04991948 ↗ |
| Modality | Cell therapy | “Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells” NCT04991948 ↗ |